Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release May 23 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it has received final approval from the USFDA for Isotretinoin Capsules in various strengths. These capsules are intended for the treatment of severe, disfiguring nodular acne and will be manufactured at the company's facility in Moraiya, Ahmedabad. The press release highlights that Isotretinoin capsules had significant annual sales in the United States, indicating a strong market presence.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 23, 2025, titled "Zydus receives final approval from USFDA for Isotretinoin Capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases